Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a sharp drop in revenues this year owing to what its boss described as a painful" push by Donald Trump to lower US weight-loss drug prices, rising competition, and the loss of important patent protections.

Denmark's Novo, once the poster-child for the growth in weight-loss treatments, said sales this year were likely to fall between 5% and 13%, ending years of double-digit gains, despite the promising launch of its new Wegovy pill in the US.